BTIG Thinks Neuronetics’ Stock is Going to Recover


BTIG analyst Marie Thibault maintained a Buy rating on Neuronetics (STIM) today and set a price target of $6.00. The company’s shares closed last Wednesday at $1.77, close to its 52-week low of $1.25.

According to TipRanks.com, Thibault is a 1-star analyst with an average return of -18.4% and a 8.3% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Varian Medical Systems, and Edwards Lifesciences.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Neuronetics with a $9.00 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $17.77 and a one-year low of $1.25. Currently, Neuronetics has an average volume of 297.1K.

Based on the recent corporate insider activity of 45 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of STIM in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Neuronetics, Inc. commercial stage medical technology company. It focuses on designing, developing and marketing products for the patients suffering from psychiatric disorders. The firm offers NeuroStar TMS, a therapy system for the treatment of major depressive disorders in adult patients. It also provides a range of support services, including patient education, practice data management system, and customer and technical services to help the client start and manage TMS therapy systems. The company was founded by Steven B. Waite, Bruce J. Shook, Norman R. Weldon and Thomas D. Weldon in April 2003 and is headquartered in Malvern, PA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts